QPS Expands Translational Medicine Unit Three-Fold to Increase Support for Biopharmaceutical, Biotechnology and CRO Partners, Address Market Demand for Gene Therapy
Newark, Delaware, February 4, 2019 – On the heels of recent FDA approvals of gene therapies in the US market, QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, today announced a three-fold expansion of its U.S.-based Translational Medicine division, which supports nucleic acid therapeutics. Gene therapies treat the underlying […]
